The IFAIN team – Prof Stephen Obaro and Prof Ehimario IGUMBOR recently paid a courtesy visit to the National Agency for Food and Drug Administration and Control (NAFDAC) as part of ongoing efforts to strengthen collaboration in pharmacovigilance and vaccine safety.

During the visit, we met with the Director General of NAFDAC, Professor Moji Christinah Adeyeye, alongside the Pharmacovigilance Team led by Dr. Uchenna Elemuwa. Discussions focused on IFAIN’s ongoing and planned work in pharmacovigilance, including the BRAVE project (Background Rates of Adverse Events for Vaccine Evaluation) in Africa, a proposed multi-country investigation into baseline rates of adverse events following vaccination.

The engagement also explored a range of potential collaborative projects where IFAIN and NAFDAC could jointly advance regulatory science, post-marketing surveillance, and evidence-based public health decision-making.

As a key outcome of the meeting, both institutions agreed to initiate the development of a Memorandum of Understanding (MoU) and to continue structured engagements to translate shared priorities into impactful action.

IFAIN remains committed to working with national regulators and global partners to strengthen health systems, improve vaccine safety monitoring, and support public trust in public health interventions.